Alzheimer's Treatment

Alzheimer's and Antidepressants: Dr. Rudy Tanzi Comments

Segment on Alzheimer's disease begins at 3:10.

Last week, many news stories broke about a recent study suggesting levels of amyloid, the sticky substance that builds up in the brain of Alzheimer's patients, may be lowered by the antidepressant Celexa. Dr. Rudy Tanzi, of Harvard Medical School/Massachusetts General Hospital and chair of Cure Alzheimer's Fund's Research Consortium, appeared on the CBS Morning Show to discuss the story.

Alzheimer's and Antidepressants: Rudy Tanzi, Ph.D. on CBS

Rudy Tanzi, Ph.D., appears on the CBS Morning Show to discuss a recent study about Alzheimer's and antidepressants.

The segment on Alzheimer's begins at 3:10.

Our Mission

Our Mission: Cure Alzheimer's Fund

An introduction to the problem of Alzheimer's and Cure Alzheimer's Fund's approach to solving it.

This video was originally shown at our 2013 Fall Symposium.

Promising Update on Efficacy and Safety of “Molecular Tweezers”

Five new publications by Gal Bitan, Ph.D., and colleagues of the David Geffen School of Medicine at UCLA have been released on developing the "molecular tweezer"* CLR01 as a therapeutic drug for Alzheimer's disease and other amyloidoses (conditions involving the build-up of insoluble amyloid proteins).

Your Alzheimer’s Questions Answered: Q&A with Rudy Tanzi

We collected your questions about Alzheimer's from our fall symposium and social media and presented them to Dr. Rudy Tanzi, chairman of our Research Consortium. Watch the videos below!

Inside the Alzheimer's Lab: Rudy Tanzi, Ph.D.

Inside the Alzheimer's Lab: Rudy Tanzi, Ph.D.

Dr. Rudy Tanzi of Harvard Medical School/Mass General Hospital talks to David Shenk about his research into CD33 inhibitors, which show promise in curtailing the damaging brain inflammation that occurs in Alzheimer's disease.

Inside the Alzheimer's Lab: David Holtzman, M.D.

Inside the Alzheimer's Lab: David Holtzman, M.D.

Dr. David Holtzman of Washington University in St. Louis explains his work on the tau protein in relation to Alzheimer's disease.

Inside the Alzheimer's Lab: Steven Wagner, Ph.D.

Inside the Alzheimer's Lab: Steven Wagner, Ph.D.

Dr. Steven Wagner, principal investigator at UC San Diego's Department of Neuroscience, talks to David Shenk about his work on modulating Abeta production.

How Close is a Treatment for Alzheimer's?

CBS News chief medical correspondent Dr. Jon LaPook and Dr. Rudolph Tanzi, professor of neurology at Harvard Medical School and director of the Genetics and Aging Research Unit at Massachusetts General Hospital, joined "CBS This Morning: Saturday."

Drug Development Strategy: Three Points of Attack

In view of an emerging consensus on how Alzheimer’s disease develops and progresses, the Cure Alzheimer’s Fund Research Consortium aggressively is focusing on three opportunities for possible intervention—at the early stage of the disease, the middle stage and the late stage. This comprehensive strategy addresses the whole picture of how Alzheimer’s disease develops and progresses, and attacks all three points simultaneously.